Pfizer receives regulatory approvals to complete the acquisition of Seagen
Announces changes in the commercial organization to incorporate Seagen and improve focus, speed and execution
Announces changes in the commercial organization to incorporate Seagen and improve focus, speed and execution
The initiation of the second clinical trial in the INTerpath program represents rapid expansion in research for additional tumor types for individualized neoantigen therapy, V940 (mRNA-4157)
This acquisition marks Max Healthcare's entry into Lucknow
Conditional marketing authorization is based on clinically meaningful response rates, duration of response, and safety from the Phase 2 MagnetisMM-3 trial
C-CAR031 is based on a novel GPC3-targeting CAR-T (AZD5851) designed by AstraZeneca using their transforming growth factor-beta receptor II
Venus Remedies is supplying the drug to many countries like Colombia, Thailand, Tanzania, Morocco, Myanmar, Indonesia, Saudi Arabia, Malaysia, Zimbabwe, Sri Lanka, Pakistan, Kenya, and Botswana
Currently, Venkat is Lead – Market Access, India at Pfizer
The full transition of Viatris' biosimilars operations to Biocon Biologics in Europe represents another significant milestone
First-ever brain chemistry database will allow clinicians to quickly infer brain biomarker data to support the diagnostic process in conditions such as Alzheimer's Disease
Subscribe To Our Newsletter & Stay Updated